Imfinzi recommended for approval in the EU for BTC
14 November 2022 07:05 GMT Imfinzi plus chemotherapy recommended for approval in the EU by CHMPas first immunotherapy regimen for advanced biliary tract cancer Positive opinion based on TOPAZ-1 Phase III trial updated survival results showingImfinzi combination reduced risk of death by 24% vs. chemotherapy alone AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus